Parnax Lab working capital

·Pharma & HealthChart ›
ProfitabilityGrowthCreditLiquidityWorking capitalDividend yieldDuPontCAGR
Per cent unless marked ×
Tap a line for its trendFY25Mar 2025FY24Mar 2024FY23Mar 2023FY22Mar 2022FY21 and earlierAlpha Plus
102.43×89.87×71.98×74.10×
FY21 and earlierEvery year the company has filed comes with Alpha Plus.
124.88×69.44×82.89×123.22×
0.30×0.34×0.33×0.35×
0.23×0.04×−0.18×−0.26×
Open the chart

From the company's filings with NSE and BSE (Ind-AS), standalone. For information only, not investment advice.

PARNAXLAB₹103.50

Parnax Lab Limited

· Pharma & Health
₹ CrorePeersBPLPHARMAJENBURPHKPLMAKERSLNOVARTINDSGRLSHUKRAPHARSUNLOC
ProfitabilityGrowthCreditLiquidityWorking CapitalYield AnalysisDuPont
Ratios — % unless marked ×
12 Months Ending
FY22
31/03/2022
FY23
31/03/2023
FY24
31/03/2024
FY25
31/03/2025
Inventory Days (DIO)74.1071.9889.87102.43
Payable Days (DPO)123.2282.8969.44124.88
Asset Turnover0.350.330.340.30
CFO/EBITDA-0.26-0.180.040.23
No consensus estimates → no Est columns. Click any row to chart it.
« ‹ › »Latest: FY25 · StandaloneFA Financial Analysis · alphave
Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreement — XBRL cross-verified ✓ 85%.